The Axxia Pharmaceuticals Difference
To achieve commercial success, an implantable drug delivery device must prevent surrounding tissue from adhering to the device. To date, no drug delivery device has prevented this occurrence. Thus, while an initial implant may be quick and easy, the possible risk of fibrotic engraftments typically requires the device removal through minor surgery, to remove both the device and also any additional tissue that has grown around the implant site. The cost, inconvenience, medical burden, and patient health risks from such surgery reduce the benefits of sustained and controlled drug administration through use of implants.
Axxia has developed a device that addresses this issue through use of silicone polymers in the outer layer of the implantable device, making it simple for the surgeon to remove and replace the implant at the end of its therapeutic life with a pair of tweezers, and far less traumatic to the patient.
Long-duration dosing (i.e ., greater than 120 days after implant), is also believed to be key to supporting cost-effectiveness arguments to healthcare payors and to support patient and physician adoption. The company’s new product in development allows for up to 180 days of consistent sustained dosing for product combinations with the right characteristics.